This newest twist from the Lykos Therapeutics saga threatens a major overhaul of the company’s approach and route, with Musk ally and billionaire Trader Antonio Gracias appearing to choose to acquire the business back again toward its nonprofit drug development roots and a far more Doblinite philosophy.“This is able to have happened up to now,